We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Admits It Infringed Patent of Amgen’s Biologic Neupogen
Teva Admits It Infringed Patent of Amgen’s Biologic Neupogen
July 22, 2011
Teva Pharmaceutical’s biosimilar of Amgen’s cancer treatment Neupogen has hit another snag as the world’s largest generic-drug maker agreed not to market its version until a month before the biologic’s patents expire in late 2013.